Hyperscale Data bitcoin treasury reaches $72.5 million, 94% of market cap
Investing.com - Jefferies has raised its price target on Divi’s Laboratories Ltd (NS:DIVI) to INR7,850 from INR7,150 while maintaining a Buy rating following the company’s September quarter results.
The pharmaceutical company reported quarterly results that exceeded Jefferies’ estimates, primarily driven by strong performance in its custom synthesis division, according to the research firm.
Jefferies noted that Divi’s generic division continues to face pricing challenges, though management expects growth to resume once new product launches begin in the next 18 months.
The outlook for the custom synthesis business remains positive, with several large projects expected to commercialize within the next 12-24 months, supporting the firm’s optimistic view.
Jefferies has increased its earnings per share estimates for fiscal years 2026-2028 by 1-6%, citing new custom synthesis projects and improved traction in existing molecules as key growth drivers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.